A novel approach to organ transplantation allowed patients to wean off anti-rejection drugs after two years, according to the results of a phase 3 clinical trial presented Monday.
Despite more people receiving organs, it’s still not enough to meet high demand. Recently, the U.S. government announced a plan to revamp the way organ recipients are chosen and organs distributed.